Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial

By A. Sacco, Ruifeng Chen, F. Worden, D. Wong, D. Adkins, P. Swiecicki, W. Chai-Ho, P. Oppelt, D. Ghosh, J. Bykowski and 9 more. 2021

Subfields: Immunology, Oncology, Otorhinolaryngology

Citations in the corpus

• Impact of T Cell Exhaustion and Stroma Senescence on Tumor Cell Biology and Clinical Outcome of Head and Neck Squamous Cell Carcinomas (2024, unknown): “Immune checkpoint inhibitors (ICIs) such as the PD-1/PD-L1 axis blockade provide new therapeutic options for recurrent or metastatic HNSCCs, but response rates remain modest with clinically relevant remissions being observed in less than 25% of cases [9,27].”